During Monday’s Current trade, Shares of Marsh & McLennan Companies, Inc. (NYSE:MMC), lost -1.12% to $52.06.
Mercer has reached a planned alliance with Transamerica whereby Transamerica will acquire Mercer’s US defined contribution (DC) administration book of business. Transamerica will also become Mercer’s preferred DC record keeping provider. The transaction is predictable to close by the end of 2015.
“We are excited about this alliance with Transamerica as both firms share a deep passion for service excellence and value delivery,” said Ken Haderer, Mercer’s Chief Operating Officer. “After the transaction is complete later this year, we will partner with Transamerica for our defined contribution recordkeeping administration business. We also want to clearly state that we are committed to ongoing to provide best of class service to our defined benefit and health clients through our own solutions.”
Marsh & McLennan Companies, Inc., a professional services firm, provides advice and solutions primarily in the areas of risk, strategy, and people worldwide. It operates in two segments, Risk and Insurance Services; and Consulting.
Shares of Parker-Hannifin Corp (NYSE:PH), declined -1.16% to $95.60, during its current trading session.
Parker Hannifin Corporation (PH), the global leader in motion and control technologies, recently unveiled a new version of its Win StrategyTM at an investor meeting in New York. The Win Strategy is the Parker business system and was originally introduced in 2001. It has been instrumental in transforming the company`s operations and optimizing performance.
Presentations at the meeting by Tom Williams, Chief Executive Officer; Lee Banks, President and Chief Operating Officer; Jon Marten, Executive Vice President - Finance and Administration and Chief Financial Officer; and Bob Bond, Corporate Vice President, e-Business, IoT, Services, laid out the details of the strategy during the half-day meeting. While many of the core principles of the strategy will remain in place, new strategies are being implemented to improve speed and performance. Key aims under the new strategy comprise:
- Engaged People - high engagement and ownership by Parker team members drives exceptional performance.
- Premier Customer Experience - moving from a service mindset to creating a great customer experience enables growth.
- Profitable Growth - implement strategies to grow organically 150 basis points faster than the market.
- Financial Performance - top-quartile financial performance as compared to our diversified industrial proxy peer group, with year-over-year earnings growth.
Parker-Hannifin Corporation manufactures and sells motion and control technologies and systems for various mobile, industrial, and aerospace markets worldwide. The company operates in two segments, Diversified Industrial and Aerospace Systems.
Kite Pharma Inc (NASDAQ:KITE), during its Monday’s current trading session decreased -1.35% to $56.25.
Kite Pharma, Inc. (Kite) (KITE) declared that Marc Better Ph.D., Vice President, Product Sciences, will present during the opening plenary session at IBC Life Sciences’ IMMUNO-ONCOLOGY: Advancing the Next Generation of Cancer Immunotherapies Conference, taking place in Alexandria, VA, September 30 - October 1, 2015. Dr. Better’s presentation, “Overcoming Challenges for Engineered Autologous T Cell Therapy,” will take place on Wednesday, September 30, 2015, at 8:15am Eastern Time. In addition, a podcast and article related to Dr. Better’s participation in the forthcoming event are accessible via the Calendar of Events section of Kite’s website at ir.kitepharma.com.
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies.
Finally, Theravance Inc (NASDAQ:THRX), decreased -2.34%, to $7.50.
laxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) declared data presented by GSK at the European Respiratory Society (ERS) International Congress (poster PA1001), from an exploratory post-hoc analysis of phase III data, which showed that patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who received Anoro® Ellipta® (UMEC/VI 62.5/25mcg) had a reduced risk of experiencing a clinically important deterioration contrast to tiotropium 18mcg or placebo over a 12-week treatment period.
This post-hoc analysis used a novel, composite endpoint, defined as a clinically important deterioration, to assess the effect of treatment on a number of factors that are each believed to represent a worsening of a patient’s COPD. The analysis examined the time to a first clinically important deterioration which was determined by the occurrence of any of the following events: A decrease in lung function of ≥100 ml from baseline as measured by trough FEV1; a deterioration in health-related quality of life defined as ≥4 unit enhance from baseline in St George’s Respiratory Questionnaire (SGRQ) total score; or the occurrence of an on-treatment moderate-to-severe COPD exacerbation.
Theravance, Inc., a royalty administration company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist partnershipagreement and the planned alliance agreement with Glaxo Group Limited (GSK).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
